The Research Of Combined Detection Of Serum CA₁₂₅, CA_19-9, CEA And AFP In Ovarian Tumors

Objective: Ovarian cancer is one of the most common gynecologic tumors. Mostpatients are the clinically advanced stage on account of the early hiding symptoms. Theoverall5-year survival rate of ovarian cancer is25%to30%, and the prognosis is notSatisfactory. The correctly assessment and promptly treatment for the ovarian cancer isimportant to improve the survival rate of patients. Serum tumor markers, an effectiveand volant method for the diagnosis of ovarian cancer, have important clinicalsignificance. Now CA₁₂₅, used to detect epithelial ovarian cancer generally, is a verycommon tumor marker, and the value has been appreciated. However, the earlydiagnosis rate of mono-detection is low, and the level of CA₁₂₅has higher degree thannormal in other benign diseases of female such as endometriosis, pelvic inflammationdisease. Therefore, combined detection increasing early diagnosis rate, sensitivity andspecificity of ovarian cancer is to become one of the contemporary research focuses.This paper explored the clinical value of combined detection of CA₁₂₅, CA_19-9, CEA,and AFP in early diagnosis of ovarian tumors.Methods: Serum tumor markers (CA₁₂₅, CA_19-9, CEA and AFP) of patients withovarian tumor, including30cases of malignant tumors and60cases of benign tumorsconfirmed by pathological examination, were detected. The other30normal individualswere as controls. The statistic difference was analyzed and the positive rates ofmono-detection and allied detection were calculated. Spss16.0software package wasused for statistical analysis. Rate was compared by t and chi-square test. Thesignificance level was set as a=0.05.Results: The mono-detection positive rate in ovarian cancer group was CA₁₂₅70.00%（42/60）, CA_19-946.67%（28/60）, CEA23.33%（14/60） and AFP13.33%（8/60）,respectively. There was statistic difference between benign tumors group and ovariancancer group. The serum levels of the four tumor markers were significantly different between the malignant tumors and controls （P<0.05）. Compared with control group,there was no statistic difference for the four tumor markers beside CA₁₂₅in the benigntumors group, The diagnostic sensitivity of single CA₁₂₅was70.00%in malignanttumors, which was much higher than other single markers, and the CA_19-9was following46.67%. The diagnostic efficiency of CA₁₂₅and CA_19-9was72.22%and57.78%,respectively. The sensitivity of combined detection of the four tumor markers fordiagnosis of malignant tumors was up to85.56%，the sensitivity and specificity was90.00%and76.67%, respectively.Conclusion: Combined detection of serum CA₁₂₅, CA_19-9, CEA and AFP canincrease positive rate of ovarian cancer, and may improve the early diagnosis of ovariantumors. The combined diagnostic method is a good way to differentiate the benign fromthe malignant ovarian tumors. It can help to reduce the false-negative and the misseddiagnose, improve the accuracy of diagnosis of the malignancy of ovarian tumors, andhave great value to earlier diagnosis.